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Down syndrome (DS), the principal cause for intellectual disability, is also associated with
hormonal, immunological, and gastrointestinal abnormalities. Muscle hypotonia (MH) and
congenital heart diseases (CHD) are also frequently observed. Collagen molecules are
essential components for maintaining muscle integrity and are formed by the assembly
of three chains, alpha 1–3. The type VI collagen is crucial for cardiac as well as skeletal
muscles. The COL α1 (VI) and α2 (VI) chains are encoded by genes located at the 21st
chromosome and are expected to have higher dosage in individuals with DS. The α 3 (VI)
chain is encoded by the COL6A3 located at the chromosome 2.We hypothesized that apart
from COL6A1 and COL6A2, COL6A3 may also have some role in the MH of subjects with
DS. To find out the relevance of COL6A3 in DS associated MH and CHD, we genotyped
two SNPs in COL6A3, rs2270669 and rs2270668, in individuals with DS. Subjects with
DS were recruited based on the Diagnostic and Statistical Manual for Mental Disorders-IV
and having trisomy of the 21st chromosome. Parents of individuals with DS and ethnically
matched controls were enrolled for comparison. Informed written consent was obtained
for participation. Peripheral blood was used for isolation of genomic DNA. Target genetic
loci were studied by DNA sequence analysis. Data obtained was subjected to population –
as well as family-based statistical analysis. rs2270668 was found to be non-polymorphic
in the studied population. rs2270669 showed significant association of the “C” allele and
“CC” genotype with DS probands having MH (P =0.02). Computational analysis showed
that rs2270669 may induce structural and functional alterations in the COL α3 (VI). Inter-
action of COLα3 (VI) with different proteins, crucial for muscle integrity, was also noticed
by computational methods. This pioneering study on COL6A3 with DS related MH thus
indicates that rs2270669 “C” could be considered as a risk factor for DS related MH.
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INTRODUCTION
Down syndrome (DS), the most common genetic cause for intel-
lectual disability is characterized by the presence of one extra
copy of the human chromosome 21 (Hsa21) (Roizen and Pat-
terson, 2003; Rachidi and Lopes, 2007). The commonly accepted
hypothesis to correlate the extra Hsa21 with DS pathophysiology
is overexpression of genes present in the Hsa21 (Chou et al., 2008).
However, changes in the expression of other euploid genes, possi-
bly due to the presence of an extra Hsa21, were also speculated to
contribute to the phenotypic variations in DS (Chou et al., 2008).
Abbreviations: AV, atrio-ventricular; BM, Bethlem myopathy; CEU, Caucasians
from Utah with ancestry from western and northern Europe; CHD, congenital
heart disease; CI, 95% confidence interval; COLVI, collagen type VI; DNA, deoxy
ribonucleic acid; DS, Down syndrome; HCB, Han Chinese from Beijing, China;
Hsa21, Human chromosome 21; IND, Indian control population; JPT, Japanese
from Tokyo, Japan; MH, muscle hypotonia; N, number of sample; OR, odds ratio;
PCR, polymerase chain reaction; RE, restriction enzyme; SNP, single nucleotide
polymorphism; UCMD, Ullrich congenital muscular dystrophy; YRI, Yoruba from
Ibadan, Nigeria.
Down syndrome, with a great variability in the penetrance level,
is characterized by complex phenotypic features, including mor-
phological abnormalities of head and limbs, short stature, hypo-
tonia, and hyperlaxity of the ligament etc. Malfunction of organs,
particularly the heart (50% of newborns with DS), gastrointesti-
nal tract obstructions or dysfunctions (4–5% of newborns with
DS), increased risk of leukemia, early onset of Alzheimer like neu-
ropathology are also common in individuals with DS (Antonarakis
and Epstein, 2006; Rachidi and Lopes, 2007). Almost all children
with DS suffer from muscle hypotonia (MH), a state of reduced
muscle tone, usually related to the skeletal muscles. Due to MH,
delay in developmental milestones, mastication problems (due
to poor neuromuscular control), muscular weakness and dental
anomalies are also of common occurrence in DS (Faulks et al.,
2008). Besides skeletal muscle abnormality, congenital heart dis-
ease (CHD) due to cardiac muscle malformation is also a frequent
problem (Klewer et al., 1998; Gittenberger-de Groot et al., 2003).
Nearly 70% of atrio-ventricular (AV) canal defects are diagnosed
in infants with DS (Korenberg et al., 1992).
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Collagen, the trimeric extracellular matrix protein, is an impor-
tant component for the formation of skeletal as well as cardiac
muscles (Gordon and Hahn, 2010). It is the most abundant pro-
tein in mammals and is found in large quantities in the tendon,
ligament, fascia, and skin (Bader et al., 2009). Collagen forms 1–2%
of muscle tissue and 6% of strong muscles with tendons (Sikorski
and Zdzislaw, 2001). As a component of the extracellular matrix, it
is also present in bone, cartilage, inter-vertebral disk, cornea, lens,
blood vessels, and intestine (Gordon and Hahn, 2010). Collagen
is comprised of three helices, α1, α2, α3, which differ from each
other in the amino acid compositions (Eastoe, 1967). Thirty dif-
ferent types of collagens based on the supra-molecular assembly
and functional properties were reported (Kumar et al., 2007).
Among different types of collagen, the type VI (COLVI) has
a crucial role in the function and stability of skeletal (Sabatelli
et al., 2001) and cardiac (Klewer et al., 1998) muscles. Assembly
of COLVI is a complex multistep process; equimolar quantities
of three genetically distinct subunits, α1(VI), α2(VI), and α3(VI),
associate to form a triple helical monomer which is then bonded
in an anti-parallel direction to form dimers. These dimers align to
form tetramers with the help of disulfide linkage (Furthmayr et al.,
1983). In humans, genes encoding for the α1 and α2 chain of type
VI collagen (COL6A1 and COL6A2 respectively) are located on the
long arm of Hsa21, 21q22.3, a region determined to be critical for
CHD associated with trisomy 21 (Francomano et al., 1991). Inves-
tigators have shown that mutations in three COL6 genes result in
Bethlem myopathy (BM), Ulrich congenital muscular dystrophy
(UCMD) (Baker et al., 2005; Lampe and Bushby, 2005), and CHD
especially in the region of AV canal (Gittenberger-de Groot et al.,
2003).
The α3 (VI) chain has a larger molecular mass than the α1 (VI)
and α2 (VI) due to additional amino acids in the carboxy-terminal
end (Bonaldo and Colombatti, 1989; Chu et al., 1990). Further,
size of the α3 (VI) chain can vary from 2970 to 3176 amino acids
due to alternative splicing of two exons (Stokes et al., 1991) and
differential initiation of transcription (Zanussi et al., 1992). It is
encoded by the COL6A3 gene (ID 1293) containing 44 exons (43
coding) and is located on the chromosome 2 (2q37.3), proximal
to the fibronectin locus (Weil et al., 1988). Being an important
part of COLVI, abnormal transcription of COL6A3 may hamper
function of the protein, thus disrupting co-ordinated regulation of
the collagen tetramer. Association of microdeletion at 2q37 with
different physical abnormalities was first presented in 1990s (Oley
et al., 1993; Wilson et al., 1995). Investigators have also reported
deletion of 2q37 in cases exhibiting CHD/MH (Rauch et al., 1996).
A number of SNPs in the COL6A3 have been investigated by
different investigators for association with BM and UCMD; sig-
nificant deleterious effect was predicted for some of these SNPs
(Lamande et al., 1999, 2006; Demir et al., 2002; Baker et al.,
2005; Baker and Rowland, 2007). However, till date, no inves-
tigation on COL6A3 has been carried out in DS patients. We
hypothesized that apart from COL6A1 and COL6A2, expected to
have an altered dosage due to trisomy of Hsa21, COL6A3 may
also have a role in DS associated MH and CHD. In order to
test the hypothesis, in this preliminary investigation we stud-
ied two missense coding SNPs in the 41st exon of COL6A3,
rs2270668 (A/G) and rs2270669 (C/G), in families with DS
probands and compared the data with ethnically matched controls.
rs2270668 (NC000002.11:g.238243481 A>G) and rs2270669
(NC000002.11:g.238243464 C>G) are located in the α3(VI) C4
domain, which has a minor role in the microfibril assembly
(Lamande et al., 2006). Since these SNPs were never reported to
have any major contribution in any disorder, we looked for their
possible contribution in DS.
MATERIALS AND METHODS
SUBJECT RECRUITMENT
Unrelated nuclear families (N = 174) with DS probands [97
complete parent-offspring trios, 63 duos (54 without father
and 9 without mother) and 14 single proband with DS] were
recruited from the Out patient Department of Manovikas Kendra,
Kolkata and Department of Paediatrics, Calcutta Medical Col-
lege, Kolkata, based on the Diagnostic and Statistical Manual of
Mental Disorders-IV (American Psychiatric Association, 1994).
Age range of the probands was 8 months to 27 years (Mean± SE
7.7± 0.51). All the DS cases recruited were confirmed for trisomy
of the 21st chromosome by karyotyping. Signs of MH and CHD
were assessed in probands by clinicians based on published litera-
ture (Morris et al., 1982; Spicer, 1984). Ethnically matched healthy
control individuals (N = 205, mean age 8.9± 0.7) without any
clinical history of intellectual disability, muscle and heart abnor-
mality were also recruited. All the individuals were engaged for
the study after obtaining informed written consent for participa-
tion. The study protocol was approved by the Institutional Human
Ethical Committee.
GENOMIC DNA ISOLATION AND GENOTYPING
Peripheral blood samples were collected from the participants and
genomic DNA was isolated using standard techniques (Miller et al.,
1988).
A 410 bp sequence of the COL6A3 gene, including the two
selected SNPs, was amplified by polymerase chain reaction using
forward primer 5′ ATTTCCTCTCTCGCTCATGC 3′ and reverse
primer 5′ TGTCTCCTTTGTGTCCTATTTGA 3′. Amplicons gen-
erated were analyzed for restriction fragment length polymor-
phism of rs2270668 and rs2270669 with HinfI and HaeIII
restriction enzymes respectively (Table 1).
STATISTICAL ANALYSIS OF GENOTYPE DATA
Simple r× c contingency table1 was used for testing the allelic
and genotypic frequencies. Minor allele frequency in the eastern
Indian control population (IND) was compared with four popula-
tions studied in the HapMap; namely, Caucasians from Utah with
ancestry from western and northern Europe (CEU), Han Chinese
from Beijing, China (HCB), Japanese from Tokyo, Japan (JPT),
and Yoruba from Ibadan, Nigeria (YRI). Odds ratio calculator2
was used for measuring allelic odds ratios. Allelic transmission
from parent to probands was analyzed by the Transmission Dis-
equilibrium Test (TDT) program of Unphased (Version 2.403)
(Dudbridge, 2003). By the TDT (Spielman et al., 1993) allelic
transmission from heterozygous parents to affected offspring can
1http://www.physics.csbsju.edu/stats/contingency_NROW_NCOLUMN_form.html
2http://www.hutchon.net/ConfidORnulhypo.htm
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Table 1 | Details of restriction fragment length polymorphism analysis.
SNP IDs Alleles RE used Cut site of REa Genotype Length of
fragments (bp)
Reaction condition
rs2270668 A/G HinfI 5′ G ANTC 3′ AA 410 5µl Amplicon incubated overnight at
37˚C with 1× Genei buffer C and 1 U
HinfI in 20µl reaction mixture, resolved
in 2.5% agarose gel
3′ CTNA G 5′ AG 410/283/127
GG 283/127
rs2270669 C/G HaeIII 5′ GG CC 3′ GG 250/160 5µl Amplicon incubated overnight at
37˚C with 1× Genei buffer C and
1 U HaeIII in 20µl reaction mixture,
resolved in 15% polyacrylamide gel
3′CC GG 5′ GC
CC
250/160/143/107
160/143/107
aBold and underlined bases are the SNP position and the black arrows are the cutting position of the restriction enzyme (RE).
Table 2 | Comparative analysis of allelic and genotypic frequencies in different populations.
Populations Allelic frequency χ2, p value Genotypic frequency χ2, p value
C G CC GC GG
CEU 0.793 0.207 4.86, 0.027 0.603 0.379 0.017 11.1, 0.004
HCB 0.756 0.244 2.91, 0.088 0.600 0.311 0.089 6.53, 0.038
JPT 0.784 0.216 4.15, 0.042 0.591 0.386 0.023 10.6, 0.005
YRI 1.000 0.000 42.4, 0.000 1.000 0.000 0.000 81.7, 0.000
IND 0.649 0.351 – 0.419 0.459 0.122 –
CEU, Caucasians from Utah with ancestry from western and northern Europe; HCB, Han Chinese from Beijing, China; JPT, Japanese from Tokyo, Japan; YRI, Yoruba
from Ibadan, Nigeria; IND, Eastern Indian control population.
Significant differences are mentioned in bold.
be calculated. Power of all the chi square tests was calculated by
Piface (Lenth, 2007).
IN SILICO ANALYSIS
Risk conferred by rs2270669 was analyzed computationally by
FastSNP3 and F-SNP4. Structural change of the protein due
to non-synonymous amino acid substitution was analyzed by
the Globplot 2.35. Interaction between COL α3 (VI) and other
proteins was analyzed using String6. Expressional correlation of
COL6A3 with other genes involved in muscle development was
analyzed by BioGPS.
RESULTS
rs2270668 was found to be monomorphic for the “A” allele in
the studied eastern Indian population (N = 189) and no further
analysis was carried out for this SNP.
rs2270669 was polymorphic and data obtained for this site was
subjected to population – as well as family-based analysis. Geno-
type frequency was in Hardy–Weinberg equilibrium for all the
groups. Comparison of allelic and genotypic frequencies revealed
significant difference for the studied IND population as compared
3http://fastsnp.ibms.sinica.edu.tw
4http://compbio.cs.queensu.ca/F-SNP/
5http://globplot.embl.de/
6http://string-db.org/
to the CEU and JPT (Table 2), principally due to an increase in the
“G” allele with a concomitant decrease in the “C” allele in the IND
population. Comparison with HCB also revealed a trend toward
increase in the “G” allele frequency in the IND population along
with a significant difference in genotypic frequencies (Table 2). As
appeared from the HapMap data, in the YRI population this site
was monomorphic for the “C” allele.
Case-control association analysis revealed an increase in the
“C” allele frequency in probands with DS as compared to eastern
Indian control subjects; however, the difference was statistically
insignificant (Table 3). Analysis of subjects sorted on the basis of
gender failed to reveal any significant difference for male probands
while female probands showed a trend toward increase in the
“C” allele and “CC” genotype (Table 3). Comparative analysis of
probands with DS sub-grouped on the basis of phenotypic char-
acteristics revealed significant increase in the occurrence of the
“C” allele (χ2= 4.86, p value= 0.027) as well as “CC” genotype
(χ2= 10.7, p value= 0.005) in probands with DS having MH
(N = 29) as compared to the controls. However, there was no sig-
nificant difference in allelic or genotypic frequencies in probands
with DS having CHD (N = 22). Probands with DS having MH
and/or CHD (N = 47) also showed significantly higher occurrence
of the “CC” genotype with concomitantly low GC/GG genotypes
in comparison to controls (χ2= 7.32, p value= 0.026).
Family-based analysis by TDTphase failed to show any
bias in transmission of any allele from the parents (from
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Table 3 | Allelic and genotypic frequencies observed in different groups.
Types Study group Allelic frequency χ2, p value OR (CI) Genotypic frequency χ2, p value
C G CC GC GG
All subjects Control
(N =205)
0.649 0.351 – – 0.419 0.459 0.122 –
Father
(N =106)
0.708 0.292 0.827, 0.363 1.318 (0.73–2.39) 0.462 0.491 0.047 3.16, 0.206
Mother
(N =151)
0.688 0.312 0.362, 0.547 1.199 (0.66–2.16) 0.450 0.477 0.074 1.46, 0.481
Proband
(N =174)
0.724 0.276 1.14, 0.287 1.38 (0.76–2.52) 0.512 0.425 0.063 2.97, 0.226
Subjects categorized
based on sex
Male Control
(N =70)
0.693 0.307 – – 0.5 0.386 0.114 –
Male Proband
(N =89)
0.708 0.292 0.952E–01, 0.758 1.1 (0.60–2.01) 0.483 0.449 0.067 1.36, 0.507
Female Control
(N =121)
0.649 0.351 – – 0.397 0.504 0.099 –
Female
Proband
(N =61)
0.754 0.246 2.38, 0.123 1.62 (0.88–2.98) 0.557 0.393 0.050 5.69, 0.058
DS with MH and/or CHD
as compared to control
Proband with
CHD (N =22)
0.727 0.273 1.50, 0.221 1.46 (0.80–2.66) 0.500 0.455 0.045 4.70, 0.096
Proband with
MH (N =29)
0.793 0.207 4.86, 0.027 2.03 (1.08–3.81) 0.621 0.345 0.034 10.7, 0.005
Proband with
CHD and/or
MH (N =47)
0.766 0.234 3.50, 0.061 1.80 (0.97–3.35) 0.574 0.383 0.043 7.32, 0.026
Control
(N =205)
0.649 0.351 – – 0.419 0.459 0.122 –
OR, odds ratio; CI, 95% confidence interval; MH, muscle hypotonicity; CHD, congenital heart disease; DS, Down syndrome.
Significant differences are mentioned in bold.
father/mother/both the parents) to the DS probands, irrespective
of the gender of the proband (Table 4). Further analysis of DS
probands having MH and/or CHD also failed to exhibit any bias
in transmission of any allele from the parents (Table 4).
Functional assessment of rs2270669 by SNPeffect revealed
that it may be responsible for changing solvent accessibility
of the protein. A potential change in splicing regulation by
SC35 (in presence of C) and SF2 (in presence of G) was also
observed. In silico analysis using String revealed that a num-
ber of proteins, important for muscle development as evidenced
from Panther pathway tool7, can interact with COLα3 (VI)
(Table 5).
Analysis by BioGPS revealed significant expressional correla-
tion of COL6A3 with COL6A1, COL6A2, COL12A1, N1D1, MMP2,
and MFAP5 (Table 6).
DISCUSSION
The α3 (VI) chain is a crucial component for skeletal as well as car-
diac muscles. Terminal deletion in chromosome 2q harboring the
COL6A3 has been reported to lead to various disease phenotypes
7http://www.pantherdb.org/pathway/
(Oley et al., 1993; Wilson et al., 1995; Rauch et al., 1996). DS related
AV canal defect was reported to be associated with abnormalities
in the COLVI and thus the molecule was speculated as an impor-
tant candidate to study cardiac muscle development also (Davies
et al., 1995; Baptista et al., 2000). Muscle related disorders like
BM were reported to be associated with mutation in exon num-
bers 4, 5, 6, 7, 40, etc. of the COL6A3 (Pepe et al., 1999; Lampe
et al., 2005). Mutation in this gene was also reported to be associ-
ated with UCMD (Demir et al., 2002). A “A>G” transition in the
splice-donor site of intron 29 was reported to cause deletion of
the exon 29 (Demir et al., 2002). A nonsense mutation in the exon
5 (R465X), resulting in a shorter N-terminal domain of COLα3
(VI), was also reported. Another nonsense mutation (R2342X),
leading to absence of collagen VI in muscle and fibroblasts, was
reported to induce a severe phenotype of UCMD (Demir et al.,
2002). However, investigation on rs2270669 in five UCMD patients
revealed presence of the derived allele in heterozygous condition
in only one individual; control individuals also showed presence
of the SNP and it was inferred that this site may not have sig-
nificant contribution in the disease etiology (Baker et al., 2005;
Baker and Rowland, 2007). The current investigation is the first
genetic association study on COL6A3 rs2270668 and rs2270669 in
subjects with DS.
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Table 4 | Frequency of rs2270669 allele transmission in families with DS probands.
Sex Parent Allele DS probands DS probands with CHD and/or MH
Transmitted Not-transmitted χ2, p value Transmitted Not-transmitted χ2, p value
All DS probands Both C 0.479 0.521 0.167, 0.683 0.523 0.476 0.048, 0.827
G 0.521 0.479 0.476 0.523
Father C 0.515 0.485 0.030, 0.862 0.500 0.500 0.000, 1.000
G 0.485 0.515 0.500 0.500
Mother C 0.424 0.576 0.761, 0.383 0.556 0.444 0.111, 0.739
G 0.576 0.424 0.444 0.556
Only male probands Both C 0.500 0.500 0.000, 1.000 0.429 0.571 0.143, 0.705
G 0.500 0.500 0.571 0.429
Father C 0.625 0.375 1.011, 0.315 0.500 0.500 0.000, 1.000
G 0.375 0.625 0.500 0.500
Mother C 0.400 0.600 0.805, 0.369 0.333 0.667 0.340, 0.560
G 0.600 0.400 0.667 0.333
Only female probands Both C 0.500 0.500 0.000, 1.000 0.571 0.429 0.287, 0.592
G 0.500 0.500 0.429 0.571
Father C 0.429 0.571 0.287, 0.592 0.500 0.500 0.000, 1.000
G 0.571 0.429 0.500 0.500
Mother C 0.600 0.400 0.403, 0.526 0.667 0.333 0.680, 0.410
G 0.400 0.600 0.333 0.667
MH, muscle hypotonicity; CHD, congenital heart disease.
Table 5 | Biological function of proteins having interaction with α3 (VI).
Proteins interacting
with COL α3 (VI)
Biological processes involved
COL6A1 Macrophage activation, blood circulation, intracellular protein transport, receptor-mediated endocytosis, signal transduc-
tion, cell–cell adhesion, cellular component morphogenesis, ectoderm development, mesoderm development, skeletal
system development, regulation of liquid surface tension, defense response to bacterium, asymmetric protein localization
LAMA2 Immune system process, muscle contraction, neurological system process, intracellular protein transport, endocyto-
sis, signal transduction, cell–cell signaling, cell-matrix adhesion, protein modification process, cell motion, ectoderm
development, mesoderm development, nervous system development, muscle organ development
ITGA7 Cell adhesion
COL1A2 Macrophage activation, blood circulation, intracellular protein transport, receptor-mediated endocytosis, signal transduc-
tion, cell–cell adhesion, cellular component morphogenesis, skeletal system development, angiogenesis, regulation of
liquid surface tension, defense response of bacterium, asymmetric protein localization
GP6 Natural killer cell activation, cell surface receptor linked signal transduction, cell–cell signaling, blood coagulation
SDC1 Macrophage activation, signal transduction, cell adhesion, mesoderm development, skeletal system development
ITGA1 Cell adhesion
CD44 Immune system process, cell communication, cell adhesion
ITGA2B Cell adhesion
rs2270668 (A/G) is responsible for a non-synonymous amino
acid change [Lys (A) to Arg (G)] at amino acid position 3006
(codon 2) in the α3 (VI) chain. In eastern Indian subjects
(N = 189), rs2270668 was non-polymorphic for the “A” allele.
In other populations studied in the 1000 genome project
(N = 208–218)8, MAF of this SNP was found to be only 0.0041.
8http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs= rs2270668
It may be inferred from the present study that this SNP does not
have any significant role in the disease etiology.
rs2270669 (C/G) is located at amino acid position 3012 (codon
1) and is responsible for a missense amino acid change from pro-
line (C) to alanine (G) in α3 (VI). In silico functional assessment
of rs2270669 by SNPeffect revealed that it may be responsible
for changing solvent accessibility of the protein. Substitution of
residues in solvent accessible surface of a protein was reported
to cause change in surface area affecting the backbone torsion
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Table 6 | Genes showing expressional correlation with COL6A3.
Gene Correlation coefficient
COL6A1 0.9071
COL6A2 0.8835
NID1 0.8377
MMP2 0.8291
MFAP5 0.8139
COL12A1 0.8107
MFAP5 0.8090
potential (Gilis and Rooman, 1996). Our study also revealed a
potential change in splicing regulation by SC35 (in presence of C)
and SF2 (in presence of G). Analysis by GlobPlot 2.3 revealed that
amino acid substitution (at 3012 amino acid position) may shorten
length of the last globular domain in the α3 (VI) chain; in pres-
ence of alanine (“G”allele) the last globular domain may be formed
from 2890 to 3072 amino acid region, while this domain comprises
of only from 2890 to 3007 amino acid region in presence of pro-
line (“C” allele). The disordered region predicted by the GlobPlot
2.3, was also changed from 3011–3021 to 3008–3021 amino acid
in presence of alanine. Therefore, the non-synonymous change in
rs2270669 could be crucial for proper structure and function of the
α3 (VI) chain. However, the predicted functional effects are low
to medium and thus may not cause significant amount of change.
Moreover, the predictions have been made based on computa-
tional models and warrants further investigation for experimental
validation.
Minor allele frequency of rs2270669 in the IND population
showed severe dissimilarity with CEU and JPT. A significant dif-
ference in genotype frequencies of the control population was
also noticed with the HCB. On the other hand, eastern Indian
subjects with DS showed an allelic distribution pattern simi-
lar to the HCB and JPT. Population of the Indian subcontinent
is highly heterogeneous (Indian Genome Variation Consortium,
2005). Subjects recruited for the present study are Indo-Caucasoid
population from of the eastern part of India and we have noticed
stark dissimilarities in genotypes of Indian population belonging
to different geographical regions (Bhaduri et al., 2007). The Indo-
Caucasoid subjects principally descends from the Euro-Caucasoid
population, while migrants from mongoloid and Afro-Negroid
population are prevalent still in the north-eastern and southern
regions of India respectively (Ghosh and Seshadri, 2005). Allele
frequency of a given SNP may get diluted by population admixer
or by natural selection pressure, thus changing significantly from
the ancestral populations. Whether this is the case for rs2270669
or is a genuine characteristic feature is a matter of conjecture at
the moment and needs further validation in extended number of
samples.
Though the present investigation showed a mild increase in the
“C” allele and “CC” genotype as well as a concomitant decrease
in the “GG” genotype in DS probands as compared to the con-
trols, the difference was statistically insignificant. No preferential
allelic distribution was found when the probands were categorized
on the basis of gender; only a slightly higher trend was noticed
for the “CC” genotype in the female probands. TDT analysis
also failed to show any bias in transmission of any allele to DS
probands from their parents. We may conclude from the present
data that probands with DS have a higher trend of occurrence of
the rs2270669 “C” allele. Whether this increase in the “C” allele is
conferring any risk needs further corroboration with large cohort
of samples.
Muscle hypotonia and CHD are common phenotypes in
DS (Morris et al., 1982; Spicer, 1984; Gittenberger-de Groot
et al., 2003). Our analysis in a limited number of subjects
revealed a highly significant increase in the “C” (χ2= 4.86, p
value= 0.027, Power= 82.5%) allele [with a high odds ratio
(OR= 2.03, CI= 1.08–3.81)] and “CC” genotype (χ2= 10.7, p
value= 0.005, Power= 97.74%) in probands with DS having MH
as compared to the controls. Among the DS probands with CHD,
an increase in“C”allele and“CC”genotype was also noticed. Com-
parison of the probands having MH and/or CHD with control
also revealed a genotypic association (with increased “CC” and
decreased “CG” and “GG” genotype; χ2= 7.32, p value= 0.026,
Power= 70.51%). Whether the “CC” genotype is conferring any
advantage to probands with DS having MH/CHD warrants further
investigation in the field.
Expression analysis showed that COL6A3 has higher expres-
sional correlation with COL6A1, COL6A2, COL12A1, N1D1,
MMP2, and MFAP5. In silico interaction analysis also showed sig-
nificant interaction of COLα3 (VI) with COL61, LAMA2, ITGA7,
SDC1, etc. COL6A1 is involved in mesoderm development, skele-
tal muscle development, cell–cell adhesion etc. and may play
an important role in cardiac and skeletal muscle development.
COL1A2 and SDC1 also have roles in mesoderm and skeletal
muscle development while LAMA2 regulates muscle contraction
and muscle organ development. COL6A1, COL6A2, LAMA2, and
SDC1 are also essential for cardiac functioning as they are involved
in events like mesoderm development and angiogenesis. Thus
COLα3 (VI) along with these proteins may have important attri-
bution in CHD and MH. Few other genes, viz. DMD, HLA-A,
HLA-B, HLA-DRB1, SPP1, PABPN1, COL6A1, DUX4, CAPN3,
FCMD, ATXN3, retrieved from the Genetic disease association
database9, may also have role in the development of muscle
disorders.
In silico analysis in the present investigation revealed that
allelic substitution of rs2270669 may alter globular domain for-
mation, solvent accessibility, and splicing of the protein. We have
also noticed an increase in the “C” allele in the DS probands,
especially in those with MH/CHD. This may lead to an alter-
ation in function of the COLα3 (VI) thus modifying the coor-
dinate functional tetrameric structure of COLVI and play a vital
role in DS related MH/muscle dysfunction. Major drawback of
the current study is the limited number of DS probands with
MH/or CHD. Additionally, hypothesis based on computational
methods need to be validated by experimental evidences. To
understand the actual role played by COL6A3, or in other
words rs2270669, in the etiology of DS related MH further
investigation is warranted in an extended cohort of subjects
with DS.
9http://geneticassociationdb.nih.gov/
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